MorphoSys Signs a Broad-Based Agreement for Use of Antibody Technologies with Merck & Co., Inc.

15-Dec-2005

MorphoSys AG announced that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD® and AutoCAL(TM) technologies in research and development of human therapeutic antibodies.

Under the terms of the agreement, MorphoSys grants Merck access to its proprietary technologies for use in Merck's drug discovery programs. Furthermore, the agreement enables Merck to develop HuCAL®-derived therapeutic antibodies in a range of indications. MorphoSys receives an up-front payment, annual user fees and R&D funding. MorphoSys is also eligible to receive license and milestone payments on projects in clinical development, and royalties on any end-products emerging from the collaboration. Further financial details were not disclosed.

During the term of the agreement, Merck will have access to the MorphoSys HuCAL GOLD® antibody library and automated screening system AutoCAL(TM) at its research sites. Merck also has access to MorphoSys's HuCAL® EST technology, which enables the rapid generation of human antibodies against newly identified proteins and an option to pursue up to ten HuCAL®-based therapeutic antibody programs.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous